CLAIMS:
We Claim:
1. Crystalline form D1 of Ibrutinib characterized by an X-ray Powder
Diffraction Pattern (PXRD) having peaks at about 10.11, 11.45, 18.47 and
20.89 ± 0.20 degrees 2Ɵ.
2. Crystalline form D1 of Ibrutinib of claim 1, further characterized by PXRD
pattern having additional peaks located at about 5.04, 10.79, 23.10 and
26.60 ± 0.20 degrees 2Ɵ.
3. Crystalline form D1 of Ibrutinib characterized by an X-ray Powder
Diffraction Pattern (PXRD) as shown figure 18.
4. A process for preparing crystalline Form D1 of Ibrutinib, comprising the
steps of:
a. obtaining a solution of ibrutinib in an alcohol;
b. combining the solution of step a) with an anti-solvent; and
c. isolating crystalline form D1 of Ibrutinib.
5. The process of claim 4 wherein, the alcohol is selected from methanol,
ethanol, propanol, isopropanol, butanol, iso-butanol and pentanol.
6. The process of claim 4 wherein, the anti-solvent is water.